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Background: Hyponatremia in the setting of cirrhosis is a common electrolyte disorder 
with few therapeutic options. The free water retention is due to non-osmotic vasopressin 
secretion resulting from the cirrhosis-associated splanchnic vasodilatation. Therefore, 
vasoconstrictive therapy may correct this electrolyte abnormality. The aim of this study 
was to assess the efficacy of midodrine and octreotide as a therapeutic approach to 
increasing urinary electrolyte-free water clearance (EFWC) in the correction of cirrhosis-
associated hyponatremia.
Methods: This observational study consisted of 10 patients with cirrhosis-associated 
hyponatremia. Hypovolemia was ruled out as the cause of the hyponatremia with a 48-h 
albumin challenge (25 g IV q6 h). Patients whose hyponatremia failed to improve with 
albumin challenge were started on midodrine and octreotide at 10 mg po tid and 100 μg 
sq tid, respectively, with rapid up-titration as tolerated to respective maximal doses of 
15 mg tid and 200 μg tid within the first 24 h. We assessed urinary EFWC and serum 
sodium concentration before and 72 h after treatment.
results: Pretreatment serum sodium levels ranged from 119 to 133  mmol/L. The 
mean pretreatment serum sodium concentration ±  SEM was 124  mmol/L ±  1.6 vs 
130  mmol/L  ±  1.5 posttreatment (p  =  0.00001). The mean pretreatment urinary 
EFWC ± SEM was 0.33 L ± 0.07 vs 0.82 L ± 0.11 posttreatment (p = 0.0003).
conclusion: Our data show a statistically significant increase in serum sodium concen-
tration and urinary EFWC with the use of midodrine and octreotide in the treatment of 
cirrhosis-associated hyponatremia.
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inTrODUcTiOn
Hyponatremia, defined by a serum sodium concentration of <135  mmol/L, is associated with 
increased morbidity and mortality in patients with cirrhosis (1–3). Approximately 22% of patients 
with cirrhosis have hyponatremia, and it is considered to be an independent predictive factor for 
survival in these patients (4, 5). At this time, the treatment of patients with hyponatremia in the 
setting of cirrhosis is limited to free water restriction due to recent concerns that tolvaptan—a 
selective vasopressin 2-receptor antagonist commonly used to treat euvolemic and hypervolemic 
hyponatremia—carries a potential risk of hepatotoxicity (6).
Decreased effective circulating volume secondary to splanchnic vasodilatation plays a central 
role in the pathogenesis of hyponatremia in patients with cirrhosis. The peripheral vasodilatation 
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hypothesis, which states that systemic vasodilation leads to a 
state of salt and water avidity, was described by Schrier et al. in 
1988 (7). The splanchnic vasodilatation and resultant reduction 
in systemic vascular resistance that causes hepatorenal syndrome 
(HRS) also lead to the development of cirrhosis-associated 
hyponatremia. The decreased effective circulating volume result-
ing from the decreased systemic vascular resistance leads to 
the upregulation of the renin–angiotensin–aldosterone system, 
norepinephrine, and vasopressin. This non-osmotic release of 
vasopressin leads to the impaired ability of the kidney to excrete 
electrolyte-free water, thereby resulting in the development of 
hyponatremia.
Given the mechanism of splanchnic vasodilatation as the 
underlying pathophysiology of HRS, several studies have 
assessed the use of vasoconstrictor therapies as treatment of HRS. 
Midodrine, which is an alpha agonist, and octreotide, a somato-
statin analog, have been shown to be effective in improving renal 
function in patients with HRS (8, 9). We propose that cirrhosis-
associated hyponatremia may respond to treatment with vaso-
constrictor therapy since the non-osmotic release of vasopressin 
is due to the underlying splanchnic vasodilatation. Increasing 
splanchnic vasoconstriction may improve the diminished effec-
tive circulating volume, which in turn would reduce vasopressin 
release, thereby allowing for more urinary electrolyte-free water 
excretion (10).
In the current study, we treated a small group of patients who 
had cirrhosis complicated by hyponatremia and ascites with 
midodrine and octreotide. The main outcome measures were 
serum sodium concentration and urinary electrolyte-free water 
clearance (EFWC).
MaTerials anD MeThODs
We performed an observational study to evaluate the efficacy of 
midodrine and octreotide in the treatment of hyponatremia in 
patients with cirrhosis. Participants in the study were recruited 
at Ronald Reagan UCLA Medical Center between December 
2013 and December 2014. The study subjects were patients 
who were referred to the renal consult service with cirrhosis-
associated hyponatremia. The study was approved by our 
institutional IRB, and informed consent was obtained from the 
participating subjects.
The inclusion criteria included patients with previous diag-
nosis of cirrhosis with ascites (as evidence of portal hyperten-
sion), age >18, serum sodium concentration of <135 mmol/L, 
and whose hyponatremia failed to improve with albumin 
challenge for 48 h. Patients whose respiratory status precluded 
withdrawal of diuretics and fluid challenge with albumin infu-
sion for 48 h and patients whose hyponatremia improved with 
albumin challenge were excluded from the study. In addition, 
exclusion criteria included requirement for renal replacement 
therapy, inability to tolerate midodrine/octreotide (e.g., brady-
cardia, nausea), and a hospital stay less than the study require-
ment (<72 h after initiation of midodrine and octreotide).
All patients are placed on 1-L fluid restriction, and all patients 
received albumin infusion (25  g IV q6  h) for 48  h to exclude 
hypovolemia as the cause of the hyponatremia. Patients whose 
hyponatremia failed to improve with albumin challenge for 
48 h were then started on midodrine (Mylan Institutional Inc., 
Rockford, IL, USA) and octreotide (Fresenius Kabi, Lake Zurich, 
IL, USA) at 10 mg po tid and 100 μg sq tid, respectively, with rapid 
up-titration as tolerated to respective maximal doses of 15 mg tid 
and 200 μg tid within the first 24 h.
Serum [Na+] and urinary [Na+] and [K+] were measured by 
ion selective electrode using the Cobas 8000 analyzer. Serum 
creatinine was measured by the enzymatic method using the 
Cobas 8000 analyzer. We recorded serum sodium level and 
serum creatinine before treatment and 72  h after initiation of 
midodrine and octreotide. Urinary sodium, potassium, and 
volume were checked in order to calculate urinary EFWC 
(11). Urinary EFWC was calculated prior to treatment and 
72  h after therapy. The primary outcome was the change in 
serum sodium concentration before and after treatment with 
midodrine and octreotide. The secondary outcome was the 
change in urinary EFWC before and after treatment with 
midodrine and octreotide.
statistics
Paired t-test (two-tailed) was performed to determine statisti-
cal significance. A p value of <0.05 was considered statistically 
significant.
resUlTs
From December 2013 to December 2014, a total of 10 patients 
were recruited into the study. All 10 patients were identified 
as having a previous diagnosis of cirrhosis with ascites (as 
evidence of portal hypertension), and they were being con-
sulted for evaluation of hyponatremia. Serum sodium levels 
prior to treatment ranged from 119 to 133 meq/L. The mean 
serum sodium concentration ±  SEM prior to treatment was 
124 meq/L ± 1.6 compared to the mean serum sodium concen-
tration of 130 meq/L ±  1.5 posttreatment (p =  0.00001). The 
mean urinary output ±  SEM pretreatment was 0.60 L ±  0.13 
vs 1.33 L ± 0.14 posttreatment (p = 0.0001) (Table 1), and the 
mean urinary EFWC ±  SEM pretreatment was 0.33 L ±  0.07 
vs 0.82  L ±  0.11 posttreatment (p =  0.0003). However, there 
was no significant difference in the mean serum creatinine 
concentration ± SEM pre- and posttreatment (1.37 ± 0.25 vs 
1.45 ± 0.28, p = 0.32).
Our 10 patients tolerated midodrine and octreotide at doses 
of 15 mg po tid and octreotide 200 μg sq tid, respectively, without 
any adverse effects.
DiscUssiOn
This study is the first to evaluate the efficacy of midodrine 
and octreotide in the correction of cirrhosis-associated 
hyponatremia. In this study, the use of midodrine and octreo-
tide significantly improved serum sodium concentration and 
urinary EFWC in our small group of patients with cirrhosis 
complicated by ascites (as evidence of portal hypertension) and 
whose hyponatremia failed to improve with albumin challenge 
for 48 h.
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Hyponatremia commonly occurs in patients with cirrhosis 
complicated by portal hypertension. In cirrhosis, the patho-
genesis of hyponatremia is thought to be related to arterial 
vasodilatation in the splanchnic circulation, which is triggered 
by portal hypertension. The presumed mechanism is that portal 
hypertension leads to increased production or activity of vaso-
dilators, mainly nitric oxide, in the splanchnic circulation. The 
splanchnic vasodilatation in cirrhotic patients results in arterial 
underfilling, and the resultant effective circulating volume deple-
tion in these patients stimulates the secretion of vasopressin. The 
increased vasopressin secretion leads to increased urinary water 
reabsorption in the collecting tubule, which in turn results in 
decreased ability of the kidney to excrete electrolyte-free water 
(EFWC). Therefore, midodrine and octreotide can be a potential 
treatment for cirrhosis-associated hyponatremia by ameliorating 
the decreased effective circulating volume resulting from the 
splanchnic vasodilatation (10).
In this study, our aim was to evaluate the efficacy of 
midodrine and octreotide in the treatment of cirrhosis-
associated hyponatremia. The patients who were included in 
our study were cirrhotic patients with ascites (as evidence of 
portal hypertension) whose hyponatremia did not improve 
with albumin challenge (25 g IV q6 h) for 48 h. Volume expan-
sion with 48  h of albumin challenge was conducted to rule 
out hyponatremia caused by hypovolemia, which often is the 
case given the frequent combination of lactulose and diuretic 
therapy in cirrhotic patients. We postulate that if midodrine 
and octreotide were to be effective in increasing splanchnic 
vasoconstriction, the improvement in the decreased effective 
circulating volume will lead to reduced non-osmotic release of 
vasopressin, thereby resulting in less urinary water reabsorption 
in the collecting tubule and increased urinary electrolyte-free 
water excretion (EFWC). The increased urinary electrolyte-
free water excretion will in turn lead to the correction of the 
hyponatremia. Indeed, treatment with midodrine and octreo-
tide in our patients resulted in an increase in serum sodium 
concentration and urinary EFWC in each patient as compared 
to pretreatment values. In our study, there was no significant 
difference in the mean serum creatinine concentration pre- and 
posttreatment (p = 0.32). The lack of significant improvement 
in serum creatinine concentration in our patients was likely 
due to the fact that 7 out of the 10 patients had fairly preserved 
renal function with serum creatinine concentration within 
the normal reference range in our laboratory (0.6–1.3 mg/dL) 
and/or the decreased muscle mass and lower rate of creatinine 
production in our cirrhotic patients.
Currently, fluid restriction is the mainstay of therapy of 
hyponatremia in cirrhotic patients. However, fluid restriction 
in patients with cirrhosis-associated hyponatremia is often dif-
ficult to achieve due to the low urinary output resulting from the 
increased vasopressin secretion. Indeed, assuming that insensible 
water loss and fecal water loss approximate the water content of 
ingested food and water of oxidation (12), electrolyte-free water 
intake must be restricted to less than urinary electrolyte-free water 
excretion (as determined by EFWC) in order to achieve negative 
free water balance (13). Strict free water restriction would there-
fore be difficult to adhere to in patients with low urinary EFWC. 
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Hence, alternative approaches should be undertaken to increase 
urinary EFWC in these cases. However, an increase in dietary 
sodium intake is not a therapeutic option in cirrhotic patients 
since it will lead to sodium and fluid retention and worsening 
ascites and peripheral edema. In addition, tolvaptan, a selec-
tive vasopressin 2-receptor antagonist commonly used to treat 
euvolemic and hypervolemic hyponatremia, is contraindicated in 
the setting of cirrhosis due to the potential risk of hepatotoxic-
ity (6). Similarly, there is concern with the use of conivaptan (a 
non-selective V1a and V2 receptor antagonist) since V1a receptor 
blockade may result in a reduction in blood pressure and may also 
compromise renal function (14). Given the limited therapeutic 
options in patients with cirrhosis-associated hyponatremia, our 
findings suggest that midodrine and octreotide may be effec-
tive in improving hyponatremia in these patients by increasing 
urinary EFWC.
limitations
Although our results showed statistically significant improvement 
in serum sodium concentration and urinary EFWC in 10 patients 
with cirrhosis-associated hyponatremia, there were significant 
limitations in our study. Our study was neither randomized 
nor blinded but rather observational in nature. In addition, our 
sample size was small. Therefore, larger randomized, controlled 
clinical trials are required to validate our findings that treatment 
with midodrine and octreotide can improve cirrhosis-associated 
hyponatremia.
cOnclUsiOn
Although the morbidity and mortality associated with cirrhosis-
associated hyponatremia are well defined, treatment remains 
limited in the form of free water restriction (5, 16–18). Given 
the dearth of viable treatment options for cirrhosis-associated 
hyponatremia, we believe that this study positively supports the 
hypothesis that vasoconstrictor therapy may help correct hypona-
tremia in cirrhotic patients with portal hypertension. To date, our 
study is the first to evaluate the use of midodrine and octreotide 
in the correction of cirrhosis-associated hyponatremia. The use of 
midodrine and octreotide significantly improved serum sodium 
concentration and urinary EFWC in our small group of patients 
with cirrhosis complicated by hyponatremia and ascites. Given 
the morbidity associated with cirrhosis-associated hyponatremia 
and the limited therapeutic options in this patient population, 
additional randomized, controlled studies are needed to sub-
stantiate the effectiveness of this novel therapeutic approach in 
cirrhosis-associated hyponatremia.
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